HT-4 - A GLOBAL APPROACH TO VASCULAR PROTECTION ACROSS SPECIALTIES: REDUCING PERSISTENT CARDIOVASCULAR RISK
Friday, October 25, 2024
1:30 PM – 1:50 PM PT
Room: Theatre 2 (Exhibit Hall)
Vascular protection is a shared clinical goal across specialties. Hear clinicians discuss their approaches and clinical decisions for preventing cardiovascular death or events in high cardiovascular risk patients with elevated triglycerides.
Learning Objectives:
At the end of this session participants will be able to:
recognize that cardiovascular risk persists in statin-treated patients and optimal cardiovascular risk management strategies are multi-faceted;
identify key clinical parameters to evaluate and stratify cardiovascular risk in patients; and
apply evidence and guidelines appropriately across different clinical settings for optimal vascular protection.
Disclosure(s):
Grace L. Chua, MD,FRCPC,FACC: Abbott: Consultant/Advisory Board (Ongoing); Eli-Lilly: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); GSK: Consultant/Advisory Board (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing), Speaker/Honoraria (Ongoing)
Subodh Verma, MD PhD FRCSC FAHA FCCS FCAHS: Amarin: Speaker/Honoraria (Ongoing); Amgen: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Astrazeneca: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Bayer: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Boehringer Ingelheim: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Canadian Medical and Surgical Knowledge Translation Research Group: Speaker/Honoraria (Ongoing); Eli Lilly: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); HLS Therapeutics: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Humber River Health: Speaker/Honoraria (Ongoing); Janssen: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Merck: Speaker/Honoraria (Ongoing); Novartis: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Novo Nordisk: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Pfizer: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); PhaseBio: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); S & L Solutions Event Management Inc: Speaker/Honoraria (Ongoing); Sanofi: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Sun Pharma: Speaker/Honoraria (Ongoing)
